Clinical commissioning policy: siltuximab for idiopathic multicentric Castleman disease (adults)

Document first published:
Page updated:
Topic:
Publication type:

Siltuximab is recommended to be available as a routine commissioning treatment option for idiopathic multicentric Castleman disease (iMCD) within the criteria set out in this document. Siltuximab is licensed for use in adults with iMCD.

Document

Clinical commissioning policy: siltuximab for idiopathic multicentric Castleman disease (adults)

Clinical commissioning policy: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 209 KB

Document

Evidence report: siltuximab for idiopathic multicentric Castleman disease (adults)

Evidence report: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 677 KB

Document

Engagement report: siltuximab for idiopathic multicentric Castleman disease (adults)

Engagement report: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 152 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): siltuximab for idiopathic multicentric Castleman disease (adults)

Equality and Health Inequalities Impact Assessment (EHIA): siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 198 KB

Document

Clinical priorities advisory group report: siltuximab for idiopathic multicentric Castleman disease (adults)

Clinical priorities advisory group report: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 240 KB

Document

Clinical panel report: siltuximab for idiopathic multicentric Castleman disease (adults)

Clinical panel report: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 83 KB

Document

Public health evidence report: siltuximab for idiopathic multicentric Castleman disease (adults)

Public health evidence report: siltuximab for idiopathic multicentric Castleman disease (adults)

  • PDF
  • 137 KB